Treatment effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in people underrepresented from the ontarget trial: Analysis of routinely collected data using trial replication methods
Baptiste PJ, Wong A, Schultze A, Cunnington M, Mann J, Clase C, Leyrat C, Tomlinson L, Wing K (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: WILEY
City/Town: HOBOKEN
Pages Range: 553-553
Conference Proceedings Title: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Involved external institutions
London School of Hygiene and Tropical Medicine
United Kingdom (GB)
GlaxoSmithKline plc. (GSK)
United Kingdom (GB)
McMaster University
Canada (CA)
United Kingdom (GB)
GlaxoSmithKline plc. (GSK)
United Kingdom (GB)
McMaster University
Canada (CA)
How to cite
APA:
Baptiste, P.J., Wong, A., Schultze, A., Cunnington, M., Mann, J., Clase, C.,... Wing, K. (2022). Treatment effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in people underrepresented from the ontarget trial: Analysis of routinely collected data using trial replication methods. In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (pp. 553-553). HOBOKEN: WILEY.
MLA:
Baptiste, Paris J., et al. "Treatment effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in people underrepresented from the ontarget trial: Analysis of routinely collected data using trial replication methods." Proceedings of the PHARMACOEPIDEMIOLOGY AND DRUG SAFETY HOBOKEN: WILEY, 2022. 553-553.
BibTeX: Download